Literature DB >> 20086003

Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

Peter Ouillette1, Samuel Fossum, Brian Parkin, Li Ding, Paula Bockenstedt, Ammar Al-Zoubi, Kerby Shedden, Sami N Malek.   

Abstract

PURPOSE: Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor of rapid disease progression and short remission duration in CLL. We conducted this study to advance our understanding of the causes of genomic complexity in CLL. EXPERIMENTAL
DESIGN: We have obtained quantitative measurements of radiation-induced apoptosis and radiation-induced ATM autophosphorylation in purified CLL cells from 158 and 140 patients, respectively, and have used multivariate analysis to identify independent contributions of various biological variables on genomic complexity in CLL.
RESULTS: Here, we identify a strong independent effect of radiation resistance on elevated genomic complexity in CLL and describe radiation resistance as a predictor for shortened CLL survival. Furthermore, using multivariate analysis, we identify del17p/p53 aberrations, del11q, del13q14 type II (invariably resulting in Rb loss), and CD38 expression as independent predictors of genomic complexity in CLL, with aberrant p53 as a predictor of approximately 50% of genomic complexity in CLL. Focusing on del11q, we determined that normalized ATM activity was a modest predictor of genomic complexity but was not independent of del11q. Through single nucleotide polymorphism array-based fine mapping of del11q, we identified frequent monoallelic loss of Mre11 and H2AFX in addition to ATM, indicative of compound del11q-resident gene defects in the DNA double-strand break response.
CONCLUSIONS: Our quantitative analysis links multiple molecular defects, including for the first time del11q and large 13q14 deletions (type II), to elevated genomic complexity in CLL, thereby suggesting mechanisms for the observed clinical aggressiveness of CLL in patients with unstable genomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086003      PMCID: PMC2818663          DOI: 10.1158/1078-0432.CCR-09-2534

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia.

Authors:  Christine Mayr; Michael R Speicher; David M Kofler; Raymund Buhmann; John Strehl; Raymonde Busch; Michael Hallek; Clemens-Martin Wendtner
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

2.  Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.

Authors:  A Carter; K Lin; P D Sherrington; M Atherton; K Pearson; A Douglas; A Burford; V Brito-Babapulle; E Matutes; D Catovsky; A R Pettitt
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

3.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

4.  Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.

Authors:  Ludovic Deriano; Olivier Guipaud; Hélène Merle-Béral; Jacques-Louis Binet; Michelle Ricoul; Gaby Potocki-Veronese; Vincent Favaudon; Zofia Maciorowski; Catherine Muller; Bernard Salles; Laure Sabatier; Jozo Delic
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

5.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

Authors:  Belinda Austen; Judith E Powell; Azra Alvi; Ian Edwards; Laura Hooper; Jane Starczynski; A Malcolm R Taylor; Christopher Fegan; Paul Moss; Tatjana Stankovic
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

6.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

7.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Thomas E Witzig; Stephanie R Fink; Robert B Jenkins; Sarah F Paternoster; Stephanie A Smoley; Kimberly J Stockero; Danielle M Nast; Heather C Flynn; Renee C Tschumper; Susan Geyer; Clive S Zent; Tim G Call; Diane F Jelinek; Neil E Kay; Gordon W Dewald
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

9.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

10.  A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

Authors:  Azra J Alvi; Belinda Austen; Victoria J Weston; Christopher Fegan; David MacCallum; Athos Gianella-Borradori; David P Lane; Mike Hubank; Judith E Powell; Wenbin Wei; A Malcolm R Taylor; Paul A H Moss; Tatjana Stankovic
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

View more
  32 in total

1.  Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; Megan Hanna; Bethany Tesar; Lillian Werner; Nathalie Pochet; John M Asara; Yaoyu E Wang; Paola Dal Cin; Stacey M Fernandes; Christina Thompson; Laura Macconaill; Catherine J Wu; Yves Van de Peer; Mick Correll; Aviv Regev; Donna Neuberg; Arnold S Freedman
Journal:  Clin Cancer Res       Date:  2012-05-23       Impact factor: 12.531

Review 2.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

3.  Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

Authors:  Peter Ouillette; Roxane Collins; Sajid Shakhan; Jinghui Li; Edward Peres; Lisa Kujawski; Moshe Talpaz; Mark Kaminski; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

4.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Valeria Spina; Alessio Bruscaggin; Sara Monti; Carmela Ciardullo; Clara Deambrogi; Hossein Khiabanian; Roberto Serra; Francesco Bertoni; Francesco Forconi; Luca Laurenti; Roberto Marasca; Michele Dal-Bo; Francesca Maria Rossi; Pietro Bulian; Josep Nomdedeu; Giovanni Del Poeta; Valter Gattei; Laura Pasqualucci; Raul Rabadan; Robin Foà; Riccardo Dalla-Favera; Gianluca Gaidano
Journal:  Blood       Date:  2012-12-13       Impact factor: 22.113

5.  ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Authors:  Matthew J J Rose-Zerilli; Jade Forster; Helen Parker; Anton Parker; Ana E Rodríguez; Tracy Chaplin; Anne Gardiner; Andrew J Steele; Andrew Collins; Bryan D Young; Anna Skowronska; Daniel Catovsky; Tatjana Stankovic; David G Oscier; Jonathan C Strefford
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

6.  High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.

Authors:  Preetesh Jain; Michael Keating; Phillip A Thompson; Long Trinh; Xuemei Wang; William Wierda; Alessandra Ferrajoli; Jan Burger; Hagop Kantarjian; Zeev Estrov; Lynne Abruzzo; Susan O'Brien
Journal:  Am J Hematol       Date:  2015-03-30       Impact factor: 10.047

7.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 8.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

9.  CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM.

Authors:  Larissa Lezina; Ruth V Spriggs; Daniel Beck; Carolyn Jones; Kate M Dudek; Aleksandra Bzura; George D D Jones; Graham Packham; Anne E Willis; Simon D Wagner
Journal:  Blood Adv       Date:  2018-08-14

Review 10.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.